Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Broggini

Showing results (101-110 of 154) with videos related to

Pageof 16
Sort By:
International Journal of Cancer|June 15, 1988
Human ovarian tumors in primary culture: growth, characterization and initial evaluation of the response to cis platinum treatment in vitroG Balconi, M Broggini, E Erba, et al.
Cancer Research|March 31, 2001
4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanismsS Marchini, G Damia, M Broggini, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 2, 2000
Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell linesG Razzini, C P Berrie, S Vignati, et al.
Cancer Research|September 15, 1987
In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureasC V Catapano, M Broggini, E Erba, et al.
Leukemia & Lymphoma|August 23, 2000
Extranodal marginal zone B-cell lymphoma genotyping by Alu-polymerase chain reactionF Bertoni, R Müllenbach, M Broggini, et al.
International Immunopharmacology|November 26, 2003
Effects of tramadol on synovial fluid concentrations of substance P and interleukin-6 in patients with knee osteoarthritis: comparison with paracetamolM Bianchi, M Broggini, P Balzarini, et al.
International Journal of Cancer|July 3, 1997
Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: possible role of p53F Vikhanskaya, L Clerico, M Valenti, et al.
Oncology Research|April 11, 2000
Microsatellite instability and frameshift mutations in genes involved in cell cycle progression or apoptosis in ovarian cancerA M Codegoni, F Bertoni, G Colella, et al.
British Journal of Cancer|February 1, 1990
DNA damage and sequence specificity of DNA binding of the new anti-cancer agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate)M Broggini, J A Hartley, W B Mattes, et al.
Neoplasia (New York, N.Y.)|August 10, 2000
Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosisP De Feudis, S Vignati, C Rossi, et al.
Pageof 16

Showing results (101-110 of 154) with videos related to

Sort By:
Pageof 16
International Journal of Cancer|June 15, 1988
Human ovarian tumors in primary culture: growth, characterization and initial evaluation of the response to cis platinum treatment in vitroG Balconi, M Broggini, E Erba, et al.
Cancer Research|March 31, 2001
4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanismsS Marchini, G Damia, M Broggini, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 2, 2000
Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell linesG Razzini, C P Berrie, S Vignati, et al.
Cancer Research|September 15, 1987
In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureasC V Catapano, M Broggini, E Erba, et al.
Leukemia & Lymphoma|August 23, 2000
Extranodal marginal zone B-cell lymphoma genotyping by Alu-polymerase chain reactionF Bertoni, R Müllenbach, M Broggini, et al.
International Immunopharmacology|November 26, 2003
Effects of tramadol on synovial fluid concentrations of substance P and interleukin-6 in patients with knee osteoarthritis: comparison with paracetamolM Bianchi, M Broggini, P Balzarini, et al.
International Journal of Cancer|July 3, 1997
Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: possible role of p53F Vikhanskaya, L Clerico, M Valenti, et al.
Oncology Research|April 11, 2000
Microsatellite instability and frameshift mutations in genes involved in cell cycle progression or apoptosis in ovarian cancerA M Codegoni, F Bertoni, G Colella, et al.
British Journal of Cancer|February 1, 1990
DNA damage and sequence specificity of DNA binding of the new anti-cancer agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate)M Broggini, J A Hartley, W B Mattes, et al.
Neoplasia (New York, N.Y.)|August 10, 2000
Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosisP De Feudis, S Vignati, C Rossi, et al.
Pageof 16